Navigation Links
Sangamo BioSciences Reports Third Quarter 2013 Financial Results
Date:10/23/2013

period in 2012. General and administrative expenses were $3.2 million for the third quarter of 2013, compared to $3.1 million for the same period in 2012. The increase in research and development expenses was primarily due to increased external expenses related to our preclinical programs, partially offset by lower clinical expenses for our SB-728-T HIV /AIDS program.

Total operating expenses for the third quarter of 2013 were $11.9 million, compared to $10.7 million for the same period in 2012. 

Nine Months ResultsFor the nine months ended September 30, 2013, the consolidated net loss was $18.5 million, or $0.34 per share, compared to a consolidated net loss of $18.8 million, or $0.36 per share, for the same period in 2012.  Revenues were $17.3 million for the nine months ended September 30, 2013, compared to $12.7 million for the same period in 2012. Total operating expenses were $35.8 million for the nine months ended September 30, 2013 compared to $31.6 million for the same period in 2012.

Recent Highlights

  • Closing of $74 Million Public Offering of Common Stock.  On September 23, Sangamo closed an underwritten public offering of 6,100,000 shares as well as 915,000 additional shares of its common stock pursuant to the full exercise of the over-allotment option granted to the underwriters. The shares were sold at the public offering price of $10.58 per share, the closing price of the stock on the date immediately prior to pricing.  The aggregate net proceeds from the offering were $69.5 million, after deducting underwriting discounts and commissions and other offering expenses.
  • Presentation of Clinical Data at ICAAC Demonstrating Sustained Functional Control of Viremia in HIV-Infected Subjects Treated With SB-728-T. The data, from its ongoing Phase 2 clinical trial (SB-728-902 Cohort 5) to evaluate  a single infusion of Sangamo's novel ZFP Therapeutic®, SB-728-T, demonstrate functi
    '/>"/>

  • SOURCE Sangamo BioSciences, Inc.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6 7 8

    Related biology technology :

    1. Sangamo BioSciences Announces Closing Of $74.2 Million Public Offering Of Common Stock And Exercise Of Over-Allotment Option
    2. Sangamo BioSciences Proposes Public Offering Of Common Stock
    3. Biotech Firms Receive Orphan Drug Designations, Release Clinical Data, Achieve Goals, Enter Acquisitions & Forecast Revenues - Research Report on Aegerion, Oncolytics, Merrimack, Sangamo, and PDL
    4. Sangamo BioSciences Announces Presentation At The 2013 Wedbush Life Sciences Management Access Conference
    5. Sangamo BioSciences Announces Presentation at the Bank of America Merrill Lynch 2013 Health Care Conference
    6. Sangamo BioSciences Announces Presentation At The Needham Healthcare Conference
    7. Sangamo BioSciences Announces Presentation At Regen Med Investor Day
    8. Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
    9. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
    10. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
    11. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:4/17/2015)... CIO Review ( http://www.cioreview.com ) has chosen ... Pharma and Life Science Technology Solution Providers 2015. The ... platform for life sciences companies. , The annual ... experts and members of CIO Review’s editorial board to ... been on our radar for some time now for ...
    (Date:4/17/2015)... NEW YORK , April 17, 2015  Guggenheim ... Guggenheim Partners, today announced the hiring of William ... research analyst. Mr. Tanner will start work ... New York office. "Bill ... and academic research, to our experienced and highly acclaimed ...
    (Date:4/17/2015)... MIAMI (PRWEB) April 17, 2015 ... attend the GTCbio Stem Cell Summit 2015 April 27 ... present the latest developments in all areas of stem ... business of stem cells and regenerative medicine. , ... clinical trials, as well as translational research in stem ...
    (Date:4/17/2015)... (PRWEB) April 17, 2015 BellBrook ... and marketing support for the powerful Orthogonal Pooled ... Chemical Genomics Center at the Lankenau Institute for ... mission is to measurably improve successful drug discovery ... by offering rare, drug-like libraries available nowhere else, ...
    Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2Guggenheim Securities Hires Biotech Analyst William Tanner in Expansion of Healthcare Coverage 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 2Global Stem Cells Group To Join GTCbio Stem Cell and Regenerative Medicine Summit in Boston, April 27-29, 2015 3BellBrook Labs and Lankenau Institute Partner to Accelerate Drug Discovery using Orthogonal Pooled Screening 2
    ... Medical Inc.,(NYSE: SMA ), a leading independent provider ... medical markets, today announced that,the filing of its 2007 ... Commission will be delayed beyond its previously announced April,14, ... stages and the work is,substantially completed. The Company said ...
    ... For 88 percent of,companies, front-line and mid-level leaders ... variety of development skills but focus,strongly on techniques ... only half of executive-level sales leaders attend the ... and,training, according to a member-driven research study conducted ...
    ... febit,today announced its newest miRNA Biochip based ... released by the Wellcome Trust Sanger Institute,yesterday. The ... information for miRNA microarray experiments., febit,s flexible ... of genomics access to the latest version of ...
    Cached Biology Technology:Symmetry Medical Extends 10-K Filing Beyond April 14, 2008 Target 2Symmetry Medical Extends 10-K Filing Beyond April 14, 2008 Target 3Developing Sales Leaders: Benchmarks Reveal Tactics that Will Propel Your Business 2febit First to Offer miRBase 11.0 Biochip 2
    (Date:4/2/2015)... At its 2015 ACMG Annual Clinical Genetics ... the American College of Medical Genetics and Genomics (ACMG) ... Board.  Members of the ACMG Board of Directors serve ... advancing its policies and programs. ACMG is the national ... an eventful time in medical genetics and genomics.  We ...
    (Date:3/31/2015)... 31, 2015  Elephant Talk Communications Corp. (NYSE MKT: ... of Software Defined Network Architecture (ET Software DNA® 2.0) ... of approximately $20.4 million for the year ended December ... for the year ended December 31, 2013. ... had completed its multi-year transition away from its legacy ...
    (Date:3/24/2015)... Markets ( http://www.researchandmarkets.com/research/kvdtcw/face_and_voice ) has announced the addition of ... report to their offering. This report analyzes the ... the following Segments: Face Biometrics, and Voice Biometrics. The report provides ... Japan , Europe , ... Africa , and Latin America ...
    Breaking Biology News(10 mins):American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 2American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 3American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 4American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 5American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 6American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 7American College of Medical Genetics and Genomics Announces New Board Members: Dr. Louanne Hudgins is ACMG President-Elect 8Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 2Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 3Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 4Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 5Elephant Talk Reports 2014 Fourth Quarter and Year End Financial Results 6Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 2Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 3Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 4Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 5Face and Voice Biometrics - Global Strategic Business Report 2015: Face Recognition Gains Prominence in Immigration Control 6
    ... among more than 100 organizations and governments led by ... Children,s Safe Drinking Water (CSDW), has helped provide ... to families in developing countries, saving an estimated 32,000 ... Allison Tummon Kamphuis, R.N., M.B.A., today described the organization,s ...
    ... , ,The use of nanopore technology aimed at more accurate ... awarded by the National Institutes of Health. The grants ... latest awarded through the National Human Genome Research Institute (NHGRI),s ... NHGRI is part of NIH. , "Nanopore technology shows ...
    ... humane option for the control of feral and stray ... by the International Society of Feline Medicine (ISFM) in ... published by SAGE. According to the society, which is ... culling to control cat populations is also rarely effective ...
    Cached Biology News:Water-purification plant the size of a fast-food ketchup packet saves lives 2New NIH awards focus on nanopore technology for DNA sequencing 2New NIH awards focus on nanopore technology for DNA sequencing 3New NIH awards focus on nanopore technology for DNA sequencing 4ISFM takes a stand on welfare of unowned cats 2
    Nuclear/Cytosol Fractionation Kit Research Focus: other Storage Temperature: 4C Shipping Temperature: 4C...
    Cytosol/Particulate Rapid Separation Kit Research Focus: other Storage Temperature: -20C Shipping Temperature: 4C...
    Request Info...
    Purified anti-human CD182 (CXCR2)...
    Biology Products: